Olive Tree People Inc. Announces The Next Big Thing - Waterless Holistic Beauty - Exclusive to 3,875 Spas in the U.S
September 01, 2022 09:33 ET
|
Oliveda International, Inc.
SANTA MONICA, CA, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Olive Tree People Inc., a subsidiary of Oliveda International, Inc. (OTC Pink: OLVI), is pleased to announce that beginning today, the company...
TELUS conclut l’acquisition de LifeWorks pour 2,3 milliards de dollars et trace une nouvelle voie pour les soins de santé axés sur l’employeur
September 01, 2022 07:45 ET
|
TELUS Health
VANCOUVER, Colombie-Britannique et TORONTO, 01 sept. 2022 (GLOBE NEWSWIRE) -- TELUS Corporation (« TELUS ») (TSX : T; NYSE : TU) a annoncé aujourd’hui la conclusion de l’acquisition par plan...
TELUS completes C$2.3 billion acquisition of LifeWorks setting a new course for employer-focused healthcare
September 01, 2022 07:45 ET
|
TELUS Health
VANCOUVER, British Columbia and TORONTO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- TELUS Corporation ("TELUS") (TSX: T; NYSE: TU) today announced the completion of the previously disclosed acquisition by...
Novo estudo publicado no Clinical Cancer Research Journal destaca o uso do teste EndoPredict para informar o tratamento em pacientes com câncer de mama na pré-menopausa
August 31, 2022 08:00 ET
|
Myriad Genetics, Inc.
O teste EndoPredict, da Myriad Genetics, identificou com precisão mulheres na pré-menopausa com câncer de mama ER+, HER2- que poderiam evitar, com segurança, a quimioterapia adjuvante SALT LAKE CITY,...
Nuevo estudio publicado en Clinical Cancer Research Journal destaca el uso de la prueba EndoPredict para informar el tratamiento en pacientes premenopáusicas con cáncer de mama
August 31, 2022 08:00 ET
|
Myriad Genetics, Inc.
La prueba EndoPredict de Myriad Genetics identificó con precisión a mujeres premenopáusicas con cáncer de mama ER+, HER2- que podrían evitar la quimioterapia adyuvante de forma segura SALT LAKE CITY,...
Un nuovo studio pubblicato sulla rivista Clinical Cancer Research mette in evidenza l’impiego del test EndoPredict per indicare quale trattamento adottare in pazienti con tumore al seno in premenopausa
August 31, 2022 08:00 ET
|
Myriad Genetics, Inc.
Il test EndoPredict di Myriad Genetics ha identificato in modo accurato le donne in premenopausa con carcinoma mammario ER+, HER2- che potevano con sicurezza evitare la chemioterapia adiuvante SALT...
Neue Studie, im Clinical Cancer Research Journal veröffentlicht, unterstreicht die Bedeutung des EndoPredict-Tests zur Information über die Behandlung von prämenopausalen Brustkrebs-Patientinnen
August 31, 2022 08:00 ET
|
Myriad Genetics, Inc.
Myriad Genetics’ EndoPredict-Test identifiziert präzise prämenopausale Frauen mit ER+, HER2-Brustkrebs, die eine adjuvante Chemotherapie vermeiden können SALT LAKE CITY, Aug. 31, 2022 (GLOBE...
Une nouvelle étude publiée dans le Clinical Cancer Research Journal met en avant l’utilisation du test EndoPredict pour éclairer les décisions thérapeutiques chez les patientes préménopausées atteintes d’un cancer du sein
August 31, 2022 08:00 ET
|
Myriad Genetics, Inc.
Le test EndoPredict de Myriad Genetics identifie avec précision les femmes préménopausées atteintes d'un cancer du sein RE+, HER2- qui pourraient éviter une chimiothérapie adjuvante sans perte de...
New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients
August 31, 2022 08:00 ET
|
Myriad Genetics, Inc.
Myriad Genetics’ EndoPredict test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid adjuvant chemotherapy SALT LAKE CITY, Aug. 31, 2022 (GLOBE NEWSWIRE)...
BioSig Strengthens Marketing and Sales Teams, Appoints National Account Executives to Scale Commercial Growth
August 30, 2022 09:37 ET
|
BioSig Technologies, Inc.
Westport, CT, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Company increases sales efforts and strategy, adds new National Account Executives to accelerate commercial growth Strengthens marketing team with...